Milestone Pharmaceuticals (MIST) Expected to Announce Quarterly Earnings on Wednesday

Milestone Pharmaceuticals (NASDAQ:MIST) is expected to be announcing its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect the company to announce earnings of ($0.18) per share and revenue of $0.8170 million for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 8:30 AM ET.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of $0.06 by ($0.26). The company had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $30.11 million. On average, analysts expect Milestone Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Milestone Pharmaceuticals Stock Performance

Shares of Milestone Pharmaceuticals stock opened at $1.18 on Wednesday. Milestone Pharmaceuticals has a one year low of $1.00 and a one year high of $3.06. The company has a market cap of $146.29 million, a price-to-earnings ratio of -1.73 and a beta of 0.98. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.09 and a current ratio of 9.18. The business’s 50 day moving average price is $1.26 and its 200 day moving average price is $1.56.

Hedge Funds Weigh In On Milestone Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MIST. Bank of America Corp DE grew its stake in shares of Milestone Pharmaceuticals by 200,550.0% in the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock worth $32,000 after acquiring an additional 16,044 shares in the last quarter. Cetera Investment Advisers acquired a new stake in shares of Milestone Pharmaceuticals in the fourth quarter valued at $42,000. Invesco Ltd. acquired a new stake in shares of Milestone Pharmaceuticals in the fourth quarter valued at $44,000. Creative Planning boosted its holdings in Milestone Pharmaceuticals by 74.6% in the second quarter. Creative Planning now owns 23,410 shares of the company’s stock valued at $45,000 after purchasing an additional 10,000 shares during the period. Finally, Raymond James Financial Inc. grew its stake in Milestone Pharmaceuticals by 30.1% during the 2nd quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock worth $84,000 after purchasing an additional 10,000 shares in the last quarter. Hedge funds and other institutional investors own 86.18% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on MIST shares. Wall Street Zen cut Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Sunday, May 17th. Raymond James Financial initiated coverage on shares of Milestone Pharmaceuticals in a research report on Friday, April 10th. They set a “strong-buy” rating and a $6.00 price target on the stock. Zacks Research upgraded Milestone Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. Wells Fargo & Company lowered their price objective on shares of Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating for the company in a research report on Thursday, May 14th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a report on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $7.25.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.